PacBio Announces PacBio Capital
New Program Expands Access to PacBio’s Highly Accurate Sequencing Systems by Providing Flexible Financing MENLO PARK, Calif., Sept. 12, 2023 /PRNewswire/ — PacBio (NASDAQ: PACB), a leading developer of high-quality,…
Press releases
PacBio Announces Collaboration with Leading Library Preparation Automation Partners
Hamilton, Integra, Revvity, and Tecan Join PacBio Compatible to Offer Verified Automated Library Prep Workflows for Whole Genome Sequencing MENLO PARK, Calif., Sept. 7, 2023 /PRNewswire/ — PacBio (NASDAQ: PACB), a…
PacBio to Present at Upcoming Investor Conferences
MENLO PARK, Calif., Aug. 9, 2023 /PRNewswire/ — PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be participating in the following upcoming…
PacBio and GeneDx Launch Research Collaboration with the University of Washington to Study Long-Read Whole Genome Sequencing for Increased Diagnostic Yield in Neonatal Care
Study is first of its kind to compare diagnostic rates across short- and long-read sequencing platforms MENLO PARK, Calif. and STAMFORD, Conn., Aug. 7, 2023 /PRNewswire/ — PacBio (Nasdaq: PACB),…
PacBio Announces Second Quarter 2023 Financial Results
MENLO PARK, Calif., Aug. 2, 2023 /PRNewswire/ — PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2023. Second quarter results Revenue of $47.6 million, a 34%…
PacBio Enters into Agreement to Acquire Apton Biosystems to Accelerate the Development of a Next Generation, High Throughput, Short-read Sequencer
PacBio will Combine Apton’s Proprietary Sequencing Technology With its Highly Accurate Sequencing by Binding Chemistry to Develop a High-Throughput Sequencer Designed to Deliver Billions of Reads per Flow Cell MENLO…
PacBio Begins Commercialization of the Onso Short-Read Sequencing System
The Onso Platform Delivers Extraordinary Accuracy Which Creates New Possibilities for Research and Translational Sequencing Applications MENLO PARK, Calif., Aug. 2, 2023 /PRNewswire/ — PacBio (NASDAQ: PACB), a leading developer of…
PacBio to Report Second Quarter 2023 Financial Results on August 2, 2023
MENLO PARK, Calif., July 19, 2023 /PRNewswire/ — PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its second quarter 2023 financial results on…
PacBio’s Revio System Empowers Bioscientia to Scale Long-Read Whole Genome Sequencing and Unravel the Mysteries of Rare Disease
Bioscientia Acquires Multiple Revio Sequencing Systems to Revolutionize Rare Disease Research by Sequencing Thousands of Long-Read Human Genomes Annually MENLO PARK, Calif., June 28, 2023 /PRNewswire/ — PacBio, a leading developer…
PacBio Announces a Private Convertible Exchange Transaction of $441 Million Principal Amount of 1.375% Convertible Senior Notes due 2030
MENLO PARK, Calif., June 26, 2023 /PRNewswire/ — Pacific Biosciences of California, Inc. ("PacBio") (NASDAQ: PACB) today announced that it has entered into a privately negotiated exchange agreement with a holder…
PacBio and Radboud University Medical Center Team Up for New Discoveries in Rare Disease Research
Collaboration Aims to Show Utility and Cost Effectiveness of HiFi Sequencing in Clinical Research Settings, Using Revio Systems MENLO PARK, Calif., June 14, 2023 /PRNewswire/ — PacBio (NASDAQ: PACB), a leading…
PacBio Announces the Appointment of Olga Troyanskaya from Princeton University to the Scientific Advisory Board
Current Member, Jay Shendure, is Appointed Chair MENLO PARK, Calif., May 30, 2023 /PRNewswire/ — PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the…
PacBio to Present at Upcoming Investor Conferences
MENLO PARK, Calif., May 25, 2023 /PRNewswire/ — PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that it will be participating in the following…
PacBio to Present at BofA Securities 2023 Health Care Conference
MENLO PARK, Calif., May 3, 2023 /PRNewswire/ — PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that it will be participating in the BofA…
PacBio Announces Record Revenue in First Quarter 2023
MENLO PARK, Calif., May 2, 2023 /PRNewswire/ — PacBio (NASDAQ: PACB) today announced financial results for the quarter ended March 31, 2023. First quarter results Revenue of $38.9 million, a…
Search
Clear filters